SELENBP1 Polyklonaler Antikörper

SELENBP1 Polyklonal Antikörper für IHC, WB,ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus

Anwendung

WB, IHC, ELISA

Konjugation

Unkonjugiert

Publikationen

1

Kat-Nr. : 27230-1-AP

Synonyme

hSBP, hSP56, LPSB, SBP, SBP56, SELENBP1, selenium binding protein 1, SP56

---

Galerie der Validierungsdaten

• 

  WB analysis of mouse liver using 27230-1-AP

  mouse liver tissue were subjected to SDS PAGE followed by western blot with 27230-1-AP (SELENBP1 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of A549 using 27230-1-AP

  A549 cells were subjected to SDS PAGE followed by western blot with 27230-1-AP (SELENBP1 Antibody) at dilution of 1:1000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human liver using 27230-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver tissue slide using 27230-1-AP (SELENBP1 Antibody) at dilution of 1:200 (under 10x lens).

• 

  IHC staining of human liver using 27230-1-AP

  Immunohistochemical analysis of paraffin-embedded human liver tissue slide using 27230-1-AP (SELENBP1 Antibody) at dilution of 1:200 (under 40x lens).

• 

  IHC staining of human lung cancer using 27230-1-AP

  Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using 27230-1-AP (SELENBP1 antibody) at dilution of 1:200 (under 10x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human lung cancer using 27230-1-AP

  Immunohistochemical analysis of paraffin-embedded human lung cancer tissue slide using 27230-1-AP (SELENBP1 antibody) at dilution of 1:200 (under 40x lens. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: Mauslebergewebe, A549-Zellen
• Erfolgreiche Detektion in IHC: humanes Lebergewebe, humanes Lungenkarzinomgewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:500-1:3000
• Immunhistochemie (IHC): IHC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• WB: See 1 publications below

Produktinformation

27230-1-AP bindet in WB, IHC, ELISA SELENBP1 und zeigt Reaktivität mit human, Maus

• Getestete Reaktivität: human, Maus
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: SELENBP1 fusion protein Ag20967
• Vollständiger Name: selenium binding protein 1
• Berechnetes Molekulargewicht: 52 kDa
• Beobachtetes Molekulargewicht: 45 kDa, 52 kDa, 56 kDa
• GenBank-Zugangsnummer: BC009084
• Gene symbol: SELENBP1
• Gene ID (NCBI): 8991
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

SELENBP1 (selenium binding protein 1,SBP1), also known as LPSB or SP56, is a 472 amino acid peripheral membrane protein that binds selenium covalently. Selenium, an essential trace element, has been shown to have an anti-cancer effect. Many reports have described a relationship between insufficient selenium intake and increased risk of cancer. Moreover, the expression of SELENBP1 has been shown to be decreased in several tumors including cancers of the prostate, lungs, colon, and ovary (PMID: 21143902, 20332323, 18272210). SELENBP1 has four isoforms with the molecular mass of 56kD, 52kD and 45kD.

Publikationen

Species	Application	Title
human	WB	BMC Gastroenterol; Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer; Authors - Cheng Zhu